Phenocopies in melanoma-prone families with germ-line CDKN2A mutations
- PMID: 29215650
- PMCID: PMC6916246
- DOI: 10.1038/gim.2017.216
Phenocopies in melanoma-prone families with germ-line CDKN2A mutations
Abstract
Purpose: Carriers of CDKN2A mutations have high risks of melanoma and certain other cancers. In this study we examined the occurrence of tumors among CDKN2A wild type (wt) members of melanoma-prone families with CDKN2A mutations.
Methods: Swedish and US melanoma-prone families with CDKN2A mutations were included. Data was collected on tumors diagnosed among family members. Among the CDKN2A mutated families, members with CDKN2A wt status who were diagnosed with melanoma were designated phenocopies.
Results: Of patients with melanoma in the CDKN2A mutated families (n = 266), 7.1%, were seen among members with CDKN2A wt status (phenocopy rate). Among the CDKN2A wt family members of the CDKN2A mutated families (n = 256), 7.4% were diagnosed with melanoma. The prospective relative risk for melanomas was significantly higher among the CDKN2A wt subjects compared with population-based controls (7.4 (95% confidence interval 1.7-33.2)), while no elevated risks of nonmelanoma cancers were seen and their offspring did not have significantly elevated risks of melanoma or other cancers.
Conclusion: Members of CDKN2A mutation carrying families who test negative for their family's mutation have moderately increased risk for melanoma and should, in addition to being considered for continuing dermatologic surveillance, be encouraged to follow sun safety recommendations and practice skin self-exams.
Similar articles
-
Pediatric melanoma in melanoma-prone families.Cancer. 2018 Sep 15;124(18):3715-3723. doi: 10.1002/cncr.31641. Epub 2018 Sep 12. Cancer. 2018. PMID: 30207590 Free PMC article.
-
CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.Int J Cancer. 2015 Nov 1;137(9):2220-6. doi: 10.1002/ijc.29595. Epub 2015 May 21. Int J Cancer. 2015. PMID: 25943250
-
Germline CDKN2A Mutation Status and Survival in Familial Melanoma Cases.J Natl Cancer Inst. 2016 Jun 10;108(11). doi: 10.1093/jnci/djw135. Print 2016 Nov. J Natl Cancer Inst. 2016. PMID: 27287845
-
MC1R variants increase melanoma risk in families with CDKN2A mutations: a meta-analysis.Eur J Cancer. 2010 May;46(8):1413-20. doi: 10.1016/j.ejca.2010.01.027. Epub 2010 Feb 26. Eur J Cancer. 2010. PMID: 20189796 Review.
-
Molecular genetics of familial cutaneous melanoma.J Clin Oncol. 1998 Feb;16(2):670-82. doi: 10.1200/JCO.1998.16.2.670. J Clin Oncol. 1998. PMID: 9469357 Review.
Cited by
-
Parent and child perspectives on family interactions related to melanoma risk and prevention after CDKN2A/p16 testing of minor children.J Community Genet. 2020 Jul;11(3):321-329. doi: 10.1007/s12687-020-00453-9. Epub 2020 Jan 18. J Community Genet. 2020. PMID: 31955387 Free PMC article.
-
Pediatric melanoma in melanoma-prone families.Cancer. 2018 Sep 15;124(18):3715-3723. doi: 10.1002/cncr.31641. Epub 2018 Sep 12. Cancer. 2018. PMID: 30207590 Free PMC article.
-
Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.J Invest Dermatol. 2020 Jan;140(1):174-181.e3. doi: 10.1016/j.jid.2019.06.138. Epub 2019 Jul 18. J Invest Dermatol. 2020. PMID: 31326397 Free PMC article.
-
Protocol to evaluate a pilot program to upskill clinicians in providing genetic testing for familial melanoma.PLoS One. 2022 Dec 7;17(12):e0275926. doi: 10.1371/journal.pone.0275926. eCollection 2022. PLoS One. 2022. PMID: 36477719 Free PMC article.
-
Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management.J Clin Med. 2021 Aug 23;10(16):3760. doi: 10.3390/jcm10163760. J Clin Med. 2021. PMID: 34442055 Free PMC article. Review.
References
-
- Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000;92:1006–10. - PubMed
-
- de Snoo FA, Bishop DT, Bergman W, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 2008;14:7151–7. - PubMed
-
- Evans DG, Howell A. Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2 mutations: more trouble with phenocopies. J Clin Oncol 2012;30:1142–3; response, 3–4. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous